I see that nobody seemed to have learned much from anti-biotics.
That should have been the first thing that they considered that anti-viral resistant forms of viruses would crop up just as the anti-biotic resistant strains of bacteria did and so not prescribed stuff like Tamiflu prophylactically.
My daughter came down with the swine flu (they could trace the transmission from someone who was tested and confirmed to have it) and my PCP wrote out a prescription for everyone in the family. She took it because she caught it within the first day or so. She knew she had been exposed so when she started showing symptoms, it was no surprise. The rest of us were exposed as well and we THINK that my youngest daughter had it as well, but aren’t sure. She wasn’t sick enough.
The article isn’t exactly correct that it would make the viruses stronger. What it would do is that if stronger strains became anti-viral resistant, they would be harder to treat and more prevalent because they couldn’t be treated, and so be more likely to kill.
BTW, did you notice that the swine flu just kind of died out on its own? It was just about the time my oldest caught it, about Oct, IIRC, and then that was about the last you heard about it. I haven’t even heard of the regular flu being much of an issue.
That seems to be the norm for flus. They run their course according to their makeup and not our arbitrary time lines.
I haven’t up-dated the main swine flu thread , I’ve been really busy..... I have been asked by other freepers to up-date it . I hope to do that soon.
There has been some recent disturbing info from Ukraine according to Dr. Niman. I posted the story and link below .
There are still current articles like the below one that was published today talking about a 3rd wave of H1N1 , and articles saying H1N1 has replaced the regular flu like this article ...
I was also asked by another freeper this question ?
Have you heard of any secondary blood infections up to 12 weeks later with H1N1?
If anyone reading this has any answers to the above question please reply back. Thanks :)
Has the flu flown the coop? Maybe, but don’t bet on it
Published Thursday January 14, 2010
By Rick Ruggles
WORLD-HERALD STAFF WRITER
http://www.omaha.com/article/20100114/LIVING07/701149875?
H1N1 flu might have muscled seasonal flu into obscurity.
Common, seasonal flu right now is almost nonexistent in Nebraska and Iowa, and it’s showing little clout elsewhere. Some medical experts in the Midwest wonder whether January, February and March, typically heavy flu months, might be virtually free of seasonal flu and may see little H1N1 activity, too.
They warn, however, that there are no promises when it comes to flu and that another wave of H1N1 might take seasonal flu’s place early this year.
“The crystal ball is fuzzy and hazy and murky,” said Dr. Tom Safranek, state epidemiologist for Nebraska.
“Influenza has a way of humiliating people who think they have a handle on this stuff.”
Doctors suspect that H1N1 flu has supplanted seasonal flu strains as the dominant flu. Historically, pandemic flu strains such as H1N1 have become the dominant strain for several years or longer, but the reason is unclear.
“For whatever reason, seasonal (flu) has not been able to compete,” said Dr. Marvin Bittner, an infectious disease specialist at Creighton University and the VA Medical Center in Omaha.
The below H1N1 article talks about permanent lung damage ...
A/H1N1 flu causes permanent lung damage to some patients in Finland
www.chinaview.cn 2010-01-14 19:17:56
http://news.xinhuanet.com/english/2010-01/14/content_12810343.htm?
HELSINKI, Jan. 14 (Xinhua) — A/H1N1 flu has caused permanent pulmonary damage to some patients in Finland, according to Finnish media report Thursday.
In Kuopio, the city situated in the middle part of Finland, five people who were in intensive care with the A/H1N1 virus developed serious lung problems. For example, one healthy 40-year-old woman’s lungs have been incurably damaged.
In these patients, the A/H1N1 virus caused viral pneumonia, which caused their lungs to fill up with liquid. When the infection recedes, the lungs can have fibrosis, or basically damaged and hardened tissue.
Kuopio’s University Hospital plans to bring every A/H1N1 flu patient who was treated in their pulmonary ward back for further testing.
Irma Koivula, an infectious diseases specialist at the Kuopio University Hospital, said that anyone who contracts A/H1N1 virus is at risk for the same kind of lung damage. She stressed that it is important to get the A/H1N1 flu vaccine, which is being offered to everyone at public health care centers in Finland.
Risk of death ten times higher in children with H1N1
12/28/20092:26 pm
Vanderbilt researcher, while working in his native country of Argentina, has found that children with H1N1 influenza die at a rate 10 times higher than those who suffer from seasonal flu.
Dr. Fernando Polack, the Cesar Milstein associate professor of Pediatrics in the Department of Pediatrics at Vanderbilt, describes the serious impact of the H1N1 influenza virus on children in an article titled Pediatric Hospitalizations Associated with H1N1 Influenza in Argentina, published in the Dec. 23, 2009, issue of the New England Journal of Medicine. The overall death rate with H1N1 was 1.1 per 100,000 children, compared to .1 per 100,000 for seasonal flu in 2007.
Polack also details which children were at highest risk. Due to Argentina’s location in the southern hemisphere, Polack was able to collect detailed surveillance data during the peak of the H1N1 virus outbreak in Buenos Aires in June. His cohort included six hospitals that combine to serve 1.2 million children.
“One thing that was striking was the tremendous impact on hospital logistics. Routine surgeries were cancelled; mass infection control practices were put in place; wards doubled— particularly in ICU’s, with everyone working over capacity. It was pretty rough,” Polack said.
Dr. Kathryn Edwards, Sarah H. Sell Chair in Pediatrics and director of the Vanderbilt Vaccine Research Program, is a coauthor on the article. Edwards says the H1N1 outbreak showcases opportunities which can result from observing opposing seasonal illness peaks from the northern to the southern hemispheres. The hope is that scientists can learn to respond more quickly to a developing pandemic.
“Flu is a global disease and we need to work together to understand and deal with each flu virus,” Edwards said.
The first author of the article is Argentinean pediatrician Dr. Romina Libster, who is currently in Nashville working as a research specialist with the VVRP. Libster said Polack realized what was happening when reports began to arise in Mexico that a new flu virus was causing serious illness.
Contact: Laurie Holloway (615) 322-474
laurie.holloway@vanderbilt.edu
Joseph Hall
HEALTH REPORTER
http://www.healthzone.ca/health/newsfeatures/swineflu/article/739405—key-to-h1n1-puzzle-look-to-molecule-17
Why did H1N1 cause some to develop pneumonia and die while leaving most with only mild flu symptoms?
The answer might lie in the elevated presence of a single molecule in those who suffered most from the virus, according to international research led by Toronto scientists.
“We’ve been doing this for many years and this is the first real clue we’ve had between severe and mild illness,” says Dr. David Kelvin, head of experimental therapeutics at Toronto’s University Health Network.
“It’s the first thing we can put our finger on and actually say ‘this is an area (where) we should intensify our research efforts,’” said Kelvin, the senior study author.
The molecule, known as interleukin 17, may be the culprit causing severe symptoms in a host of seasonal influenzas and other respiratory ailments like SARS, he said.
The study appears this week in the journal Critical Care.
H1N1 has caused 390 deaths in Canada since first emerging in late April. The World Health Organization has estimated at least 9,596 people worldwide have died.
Looking at a group of otherwise healthy Spanish patients during H1N1’s initial appearance, the study found that those with severe symptoms also had elevated levels of interleukin 17.
Known as a cytokine, the molecule is one of several that help regulate the body’s immune response to viruses and bacteria. But interleukin 17 is also associated with such inflammatory autoimmune diseases as rheumatoid arthritis and asthma, Kelvin said.
It is this inflammatory function that is likely at play in flu sufferers with elevated levels, he said. “When we found that there were high levels of (interleukin 17) in severe patients and not in the mild patients, we thought that was a clue to what was driving the inflammation in the lungs of those severe patients.”
Kelvin said it is not known whether high levels of the molecule are always present in the severe flu patients, or if they simply produce more in response to the virus. In either case, the molecule has rich potential as a screening target to predict which H1N1 sufferers will develop severe disease, said Ted Ross of the University of Pittsburgh’s Center for Vaccine Research.
“If it’s high early in infection, it looks like you’re going to have a more severe outcome and therefore you can screen patients,” said Ross, in commenting on the paper.
Ross said interleukin 17 also presents a promising target for new drugs that could help patients recover from H1N1 pneumonias.
“I think it would be very useful as a screening-type tool and I also think that some time in the future therapies that target (interleukin 17) may be very helpful, not only in this illness but in other viral illnesses.”
There are already drugs in animal trials that are proving successful at blocking the actions of interleukin 17. These might soon be available for human trials, Ross said.
As well, people who tested positive for high interleukin 17 levels early in the ailment’s progression could be given higher doses of antiviral drugs like Tamiflu.
Kelvin also said people known to produce higher levels could go to the top of any vaccine lineups as new pandemic viruses emerge.
While the study was conducted on Spanish patients, much of the blood analysis that pointed to interleukin 17 was done in Kelvin’s Toronto lab. Further studies are being conducted in China and other countries.
December 16, 2009 - Toronto Star - excerpts
“Why did H1N1 cause some to develop pneumonia and die while leaving most with only mild flu symptoms? The answer might lie in the elevated presence of a single molecule in those who suffered most from the virus, according to international research led by Toronto scientists. “We’ve been doing this for many years and this is the first real clue we’ve had between severe and mild illness,” says Dr. David Kelvin, head of experimental therapeutics at Toronto’s University Health Network.
“It’s the first thing we can put our finger on and actually say ‘this is an area (where) we should intensify our research efforts,’” said Kelvin, the senior study author. The molecule, known as interleukin 17, may be the culprit causing severe symptoms in a host of seasonal influenzas and other respiratory ailments like SARS, he said. The study appears this week in the journal Critical Care.
It is this inflammatory function that is likely at play in flu sufferers with elevated levels, he said. “When we found that there were high levels of (interleukin 17) in severe patients and not in the mild patients, we thought that was a clue to what was driving the inflammation in the lungs of those severe patients.”
Kelvin said it is not known whether high levels of the molecule are always present in the severe flu patients, or if they simply produce more in response to the virus. In either case, the molecule has rich potential as a screening target to predict which H1N1 sufferers will develop severe disease, said Ted Ross of the University of Pittsburgh’s Center for Vaccine Research.”
Commentary
Ukraine Fatalities Jump to 940 - Over 4 Million Infected
Recombinomics Commentary 13:20
January 12, 2010
4,106,091 Influenza/ARI
242,246 Hospitalized
940 Dead
The above tally is the latest from the Ukraine Ministry of Health website. The number dead has increased by 22 in the past 24 h and 42 in the past 48 h, which is close to one death per hour, even though the number of cases per day has decline so only 5 of the 27 regions remain above the epidemic threshold. In the past 2 days there were 7 deaths recorded for Kyiv and 6 for Donetsk, which now has 134 deaths (see map).
The high rate of fatalities is of concern because of the high frequency of fatal cases with receptor binding domain changes. Although several countries have a case fatality rate for H1N1 patients with D225G/N, in Ukraine all 8 sequences from fatal cases have D225G, D225N, or both.
Moreover, similar changes are being reported for adjacent regions in Russia and Moldova, and spikes in fatalities are also being reported in countries in the region, including a cluster in Romainia
Ukraine is being careful watched because of concerns that the sub-clade with these receptor binding domain changes will became more common, leading to a higher rate of severe and fatal cases. Recent sequences from the Kyiv area had both D225G and D225N, which corresponds to the spread of fatal H1N1 cases.
Sequences from fatal cases in eastern Ukraine would be useful.
link is http://www.recombinomics.com/News/01121002/Ukraine_940.html